The purpose of this paper is to design an injectable
hydrogel containing
nanodrugs for combined chemotherapy and photothermal therapy of tumors.
Pluronic F127 was oxidized to aldehyde-terminated (AF127) as a precursor
of the hydrogel. AF127 reacts with carboxymethyl chitosan to form
a dynamic imine bond, thereby obtaining a hydrogel. Sorafenib and
ICG were coassembled into a pure nanodrug (S–I NP) capable
of combined chemotherapy and photothermal therapy (PTT). By incorporation
of S–I NPs into the hydrogel, an injectable pH/temperature
dual-responsive nanoparticle-hydrogel composite (S–I NPs@Gel)
was obtained. S–I NPs@Gel can form a drug reservoir at the
tumor site and gradually release S–I NPs in response to the
tumor microenvironment. Sorafenib, a multitargeted antitumor drug,
inhibits cell proliferation and induces apoptosis in liver cancer
cells. ICG serves as an effective photosensitizer, absorbing near-infrared
light to induce strong photothermal effects while generating reactive
oxygen species (ROS) that induce cell apoptosis. MTT assay results
demonstrate that S–I NPs@Gel exhibits the highest cell toxicity
under laser irradiation, reaching 93.3%. Antitumor treatment results
reveal that the tumor volume treated by S–I NPs@Gel under irradiation
(808 nm, 2 W/cm2, 5 min) was only 382.9 ± 80.5 mm3, achieving a tumor growth inhibition rate of 93.5%. Thus,
a locally administered system based on pH and temperature-sensitive
hydrogels can effectively achieve synergistic antitumor effects.